ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ABUS Arbutus Biopharma Corporation

2.71
0.03 (1.12%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Arbutus Biopharma Corporation NASDAQ:ABUS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 1.12% 2.71 2.50 3.35 2.85 2.70 2.71 683,613 05:00:00

Arbutus to Participate at JMP Securities Life Sciences Conference

13/06/2019 1:30pm

GlobeNewswire Inc.


Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Arbutus Biopharma Charts.

Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat at JMP Securities Life Sciences Conference at 10:00 am ET on Thursday, June 20, 2019.

A live webcast of the fireside chat can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.  A replay of the webcast will be available for 90 days following the live presentations.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information

Investors

Mark MurrayPresident and CEOPhone: 604-419-3200 Email: ir@arbutusbio.com

Pam Murphy Investor Relations ConsultantPhone: 604-419-3200Email: ir@arbutusbio.com

1 Year Arbutus Biopharma Chart

1 Year Arbutus Biopharma Chart

1 Month Arbutus Biopharma Chart

1 Month Arbutus Biopharma Chart

Your Recent History

Delayed Upgrade Clock